An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)

NCT01344889 · clinicaltrials.gov ↗
COMPLETED
Status
4459
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Hoffmann-La Roche